GlassScriptPhysician profile
Duane Jay Henk
NPI 1982756763
$1,980.72
in general payments reported to CMS, 2019-2025
30 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $136 · 2021: $310 · 2022: $463 · 2023: $379 · 2024: $267 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $294.91 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $238.50 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.22 | 2021-2025 | |
| Novo Nordisk INC | $164.07 | 2019-2025 | Wegovy, Ozempic |
| Amgen INC. | $107.33 | 2019-2021 | |
| Glaxosmithkline, LLC. | $100.08 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $89.10 | 2021-2023 | Spravato |
| Abbvie INC. | $70.84 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.45 | 2022-2025 | Synjardy, Tradjenta, Jardiance |
| Medtronic, INC. | $61.36 | 2024-2025 | Intellis Adaptivestim |
| Eisai INC. | $59.92 | 2021-2025 | |
| Boston Scientific Corporation | $57.38 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $57.03 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $46.81 | 2021-2025 | Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.77 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $31.77 | 2022 | |
| Dexcom, INC. | $31.51 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $29.35 | 2023 | Trulicity, Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $28.56 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.53 | 2021 | |
| Acadia Pharmaceuticals INC | $23.25 | 2025 | Nuplazid |
| Atricure, INC. | $18.09 | 2024 | |
| Horizon Therapeutics Plc | $16.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.79 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.80 | 2020 | |
| Amarin Pharma, INC. | $13.15 | 2020 | |
| Almatica Pharma LLC | $12.59 | 2022 | |
| Astellas Pharma US INC | $12.49 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.09 | 2020 | |
| Adlon Therapeutics L.P. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Henk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.